In an early September bulletin we reported on the DEA’s proposal to significantly increase the production quota for research psilocybin for 2021. Then, in mid-October, we covered the Administration’s proposal to greatly increase psychedelic production quotas for next year, 2022. In its earlier proposed increases to the 2021 quotas, the DEA expressed plans to increase psilocybin production to 1…


Previous articleTryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
Next articleNuminus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021